Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

BACKGROUND: Vedolizumab (ENTYVIO) is a humanized α(4)β(7) integrin antagonist approved for the treatment of inflammatory bowel disease, which selectively blocks gut-specific lymphocyte trafficking. We evaluated the risk of opportunistic infections of interest in patients treated with vedolizumab. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Siew C, Hilmi, Ida Normiha, Blake, Aimee, Bhayat, Fatima, Adsul, Shashi, Khan, Qasim Rana, Wu, Deng-Chyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185254/
https://www.ncbi.nlm.nih.gov/pubmed/30312414
http://dx.doi.org/10.1093/ibd/izy153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185254/
https://www.ncbi.nlm.nih.gov/pubmed/30312414
http://dx.doi.org/10.1093/ibd/izy153

Ejemplares similares